South Korea's Genexine licensed China rights for a novel long-acting EPO drug to Shanghai Fosun Pharma unit Shanghai ChemoWanbang Biopharma, which follows team efforts in other therapeutic areas with Indonesia's Kalbe Farma and China's Tasly late last year.
GlaxoSmithKline has been quietly working on bioelectronic medicines for years--after having established an R&D; unit dedicated to it in 2012, which was followed by a $50 million venture fund in 2013, and then a $5 million innovation challenge in 2014. Although it hasn't disclosed much about the fruits of its efforts, it has done a new deal to add to them.
Cook Medical is recalling 17,827 single-lumen central venous catheters and pressure monitoring sets and trays because of concerns about catheter tip fracture and/or separation. The FDA posted the Bloomington, IN's company's recall on its website, an action it takes from time to time to publicize recalls that are critical to patient safety.
Icon has become the first contract research company to help manage the reams of big data coming from the U.K.'s unique private-public partnership Genomics England.
More than a year after Cerus gained FDA approval--now the American Red Cross has bought into its technology with a multi-year deal for its Intercept Blood System for pathogen reduction in platelets and plasma. It's responsible for about 40% of the U.S. blood products, delivering 1.1 million plasma and 780,000 platelet units last year to almost 2,600 hospitals and transfusion centers.
Cambridge, MA, startup Synlogic signed its first major pharma partnership, teaming up with AbbVie in a multiyear collaboration in hopes of developing new treatments for inflammatory bowel disease.
Medtronic signaled its interest in abdominal aortic aneurysm repair last year with the $110 million acquisition of Aptus Endosystems and investment in Arsenal AAA in return for an option to acquire the company. Now Medtronic says the first patient was treated in its trial of the Valiant TAAA Stent Graft System for thoracoabdominal aortic aneurysm.
French drug delivery specialist MedinCell is teaming up with Novartis' generic division Sandoz to develop controlled-release drugs with a focus on cancer.
Struggling injection device specialist Unilife said in an SEC filing that it needs an additional week to negotiate a deal with potential savior Amgen, which would involve the big biotech purchasing up to 19.9% of the company's stock in return for a much-needed cash infusion. If the grand alliance pans out, Amgen would also gain the preferred right of access to new drug delivery platforms and enter into a manufacturing arrangement with Unilife.
The U.K.'s National Health Service hasn't exactly earned high marks so far for its efforts on the digital health front. Its prior efforts to convert to electronic medical records have failed. But the health program is redoubling its efforts now by committing £4.2 billion ($6 billion) to a variety of digital health initiatives. That news comes on the heels of the agency announcing a series of 7 med tech-focused trials with major technology partners including Alphabet's Verily, Royal Philips and Accenture.